Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.65 |
| ▸ | AOC1 | P19801 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624793 | 0.91 | KIF11 (0.78) | KIF11AOC1KDM4EGAAEGFR | |
| SCHEMBL3623088 | 0.84 | KIF11 (0.65) | KIF11EGFR | |
| SCHEMBL3613719 | 0.83 | KIF11 (0.85) | KIF11AOC1 | |
| SCHEMBL3620943 | 0.82 | KIF11 (0.78) | KIF11AOC1KDM4EGAA | |
| SCHEMBL3618674 | 0.80 | KIF11 (0.71) | KIF11KDM4EGAAEGFR | |
| SCHEMBL3622572 | 0.80 | KIF11 (0.71) | KIF11 | |
| SCHEMBL3624192 | 0.77 | KIF11 (0.78) | KIF11KDM4EGAA | |
| SCHEMBL3622144 | 0.76 | KIF11 (0.58) | KIF11EGFR | |
| SCHEMBL4321033 | 0.76 | KIF11 (1.00) | KIF11AOC1 | |
| SCHEMBL3627575 | 0.76 | KIF11 (1.00) | KIF11AOC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119484-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | claimed |
| US-7745639-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20050119484-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119484-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF23 | KIF11 8/4885AOC1 4404/4885KDM4E 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.